1548 — Genscript Biotech Income Statement
0.000.00%
Last trade - 00:00- HK$27.03bn
- HK$22.73bn
- $959.53m
Annual income statement for Genscript Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 490 | 626 | 560 | 594 | 960 |
| Cost of Revenue | |||||
| Gross Profit | 283 | 304 | 271 | 272 | 553 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,005 | 1,044 | 386 | 757 | 1,413 |
| Operating Profit | -515 | -418 | 175 | -163 | -453 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -517 | -432 | 169 | -171 | -471 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -518 | -428 | 163 | -174 | -532 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -359 | -227 | -95.5 | 2,962 | -533 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -359 | -227 | -95.5 | 2,962 | -533 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.175 | -0.104 | 0.206 | -0.017 | -0.126 |